Small-Molecule Targeted Cancer Therapies: World Market 2013-2023

Date: December 10, 2012
Pages: 174
US$ 2,400.00
License [?]:
Publisher: Visiongain
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S38E2C9843EEN

Download PDF Leaflet

Small-Molecule Targeted Cancer Therapies: World Market 2013-2023
Report Details

Cancer treatment with small molecules - your guide to trends and revenue prospects

What does the future hold for small targeted agents to treat cancers? Visiongain's updated report gives you revenue predictions to 2023. There you find sales data, R&D trends, opportunities and commercial prospects.

You see the potential of those molecularly-targeted technologies and products. Our new analysis lets you assess forecasted sales at overall world market, product and national level. Discover how and why revenues can increase.

Forecasts and other analyses to help you find the best growth opportunities

In our study you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis (SWOT and STEP), business news, outlooks and developmental trends (R&D). You gain 72 tables, 34 charts and four research interviews.

You can stay ahead in knowledge, benefiting your research and analyses. Much scope remains for medicines to combat growth, progression and spread of tumours (tumors). Our work lets you investigate the most promising areas of that drug industry and market.

The following sections show what you discover in our report.

You see prospects for the world market and top products

Along with predictions of overall world market value, you see revenue forecasts for 10 leading brands at world level. You find data from 2011 to 2023 for these products:
  • Glivec (Gleevec)
  • Revlimid
  • Alimta
  • Velcade
  • Tarceva
  • Taxotere
  • Sutent
  • Nexavar
  • Sprycel
  • Arimidex
You find analysis of competition, as well as commercial drivers and restraints. Discover the potential of those targeted applications of oncology.

Our work also breaks the overall world forecast into prominent national markets.

What are the prospects in leading countries?

There are many opportunities in developed and developing countries, our report explains.

You discover individual revenue forecasts to 2023 for nine national markets, seeing relevant overall sales:
  • US
  • Japan
  • Germany, France, UK, Italy and Spain (EU5)
  • India and China.
See what's likely to happen. There will be strong growth in established markets and in developing countries, our analyses show. You find areas with highest potential.

China and India, in particular, will achieve high revenue growth. Other markets - including the US - will also expand fast. Launch of new products will stimulate growth worldwide.

What about the oncology R&D pipeline for those drugs?

You see developmental trends for treating many cancers (lung, breast, colorectal, stomach, multiple myeloma and prostate, among others):
  • Kinase inhibitors and signal transduction blockers
  • VEGF agents and androgen receptor antagonism
  • Signal transduction blocking and proteasome inhibition candidates
  • Immunomodulators, aurora kinase inhibiting and peptide prodrugs
  • Gene expression, epigenetic treatments and cellular function regulators
  • E-selectin antagonists and histone deacetylase inhibitors.
Our work also discusses these technologies and others, including pharmacogenomics:
  • Mitosis inhibitors and apoptosis inducers
  • HDAC mechanisms and other drug targets
  • Heat shock protein (HSP) modulators
  • Hormones and angiogenesis blockers
  • Transcription factor regulators and siRNA processes and products
  • Biomarkers, genome screening and molecular diagnostics (inc. theranostics)
R&D pipelines for targeted therapies are vast and strong. Discover progress for injectable and oral medicines, including antineoplastics. Also, you see outlooks for treating solid tumours and other forms. You gain insight into developments and their significance.

Emerging technology holds great promise. Many opportunities exist for large companies and specialty pharma firms, allowing market expansion from 2013.

Leading companies and market value in 2016

Overall world revenue for that market area will reach $32.7bn in 2016, our report forecasts. We predict strong revenue growth to 2023, owing to rising demand for anti-cancer medicines. Rising disease incidence and prevalence will stimulate market growth.

In our study you find discussions of Novartis, Eli Lilly, Roche, Pfizer, Takeda and many other developers and manufacturers. You find outlooks for revenue growth.

This decade, many opportunities will arise for pharmaceutical and biotechnology companies in targeted cancer treatment. Our work shows you the commercial possibilities.

Nine ways Small-Molecule Targeted Cancer Therapies: World Market 2013-2023 helps you

To sum up, our investigation gives you the following knowledge on the topic:
  • Forecasted revenues to 2023 for the overall world market - you discover the industry's future prospects
  • Predicted revenues of 10 leading products to 2023 - you analyse crucial developments for top brands
  • Market forecasting to 2023 for US, Japan, Germany, France, UK, Spain, Italy, India and China - you see national sales outlooks
  • Review of R&D pipelines by treatment area and technology - you hear about progress in established and emerging research areas
  • Assessment of companies - you find activities, products, strategies and outlooks
  • Opinions on the sector - you discover our interviews with authorities in the field
  • Competition and opportunities influencing sales - you see what affects the future
  • Discussions of what stimulates and restrains the industry and market - you assess business trends, drivers and restraints
  • Prospects for established firms and specialists seeking to enter the sector - you see factors and outlooks for success.
You gain information found nowhere else

That work gives independent analysis from our primary and secondary research. You receive business intelligence found only in our study, seeing where prospects are lucrative.

With our report you are less likely to fall behind in knowledge or miss opportunity. Discover how our work could benefit your research, analyses and decisions, saving you time and getting you recognition for commercial insight.

Ordering now lets you discover prospects to 2023 for small-molecule anti-cancer drugs

Visiongain's study is for everyone needing analysis of oncology and the market for cancer treatments. You find data, trends and predictions. Please ask for our report now.

1.1 Overview of Findings
1.2 Scope and Format of the Report
1.3 Research and Analysis Methods


2.1 Targeted Cancer Therapies
2.2 The Physiology of Cancer
  2.2.1 Uncontrolled Growth
  2.2.2 Dedifferentiation
  2.2.3 Invasiveness and Metastasis
  2.2.4 Causes of Cancer
2.3 Incidence and Mortality for Cancer
  2.3.1 Incidence
  2.3.2 Mortality
  2.3.3 Survival The Developed World The Developing World
2.4 Treating Tumours
  2.4.1 Chemotherapy
  2.4.2 Traditional Antineoplastics
  2.4.3 Novel Antineoplastics Kinase Receptor Antagonists Other Novel Antineoplastics
  2.4.4 Hormone Therapies
  2.4.5 Active Immunotherapy
  2.4.6 Passive Immunotherapy: Monoclonal Antibodies
2.5 Small-Molecule Targeted Cancer Therapies
  2.5.1 Signal Transduction Inhibitors
  2.5.2 Gene Expression and Other Cellular Function Regulators
  2.5.3 Small-Molecule Apoptotic Inducing Drugs
  2.5.4 Angiogenesis Blockers
2.6 Targeted Cancer Therapies: Small-Molecule Drugs


3.1 The World Small-Molecule Cancer Therapies Market in 2011
3.2 Growing Market for Small-Molecule Cancer Therapies
  3.2.1 Sales Forecast for Small-Molecule Cancer Therapies, 2012-2016
  3.2.2 Sales Forecast for Small-Molecule Cancer Therapies, 2017-2023
3.3 Leading Products in the Small-Molecule Cancer Therapies Market


4.1 The US Small-Molecule Cancer Therapies Market, 2012-2023
4.2 The Japanese Small-Molecule Cancer Therapies Market, 2012-2023
4.3 The Leading European Small-Molecule Cancer Therapies Markets, 2012-2023
4.4 Emerging-Economy Small-Molecule Cancer Therapies Markets
4.5 The Chinese Small-Molecule Cancer Therapies Market, 2012-2023
4.6 The Indian Small-Molecule Cancer Therapies Market, 2012-2023
4.7 Summary of Market Forecasts


5.1 Glivec/Gleevec (Novartis)
  5.1.1 Glivec/Gleevec Sales 2011
  5.1.2 Glivec/Gleevec Sales Forecast, 2012-2016
  5.1.3 Glivec/Gleevec Sales Forecast, 2017-2023
  5.1.4 Tasigna Set to Replace Glivec/Gleevec
5.2 Revlimid (Celgene)
  5.2.1 Revlimid Sales 2011
  5.2.2 Secondary Malignancies
  5.2.3 Revlimid Sales Forecast, 2012-2016
  5.2.4 Revlimid Sales Forecast, 2017-2023
5.3 Alimta (Eli Lilly)
  5.3.1 Alimta Sales 2011
  5.3.2 Patent Disputes
  5.3.3 Alimta Sales Forecast, 2012-2016
  5.3.4 Alimta Sales Forecast, 2017-2023
5.4 Velcade (Takeda/J&J)
  5.4.1 Velcade Sales 2011
  5.4.2 Recent Developments
  5.4.3 Velcade Sales Forecast, 2012-2016
  5.4.4 Velcade Sales Forecast, 2017-2023
5.5 Tarceva (Roche)
  5.5.1 Tarceva Sales 2011
  5.5.2 Patent Expiry
  5.5.3 Tarceva Sales Forecast, 2012-2016
  5.5.4 Tarceva Sales Forecast, 2017-2023
5.6 Taxotere (Sanofi)
  5.6.1 Taxotere Sales 2011
  5.6.2 Patent Expiry
  5.6.3 Taxotere Sales Forecast, 2012-2016
  5.6.4 Taxotere Sales Forecast, 2017-2023
5.7 Sutent (Pfizer)
  5.7.1 Sutent Sales 2011
  5.7.2 Generics Challenges
  5.7.3 Sutent Sales Forecast, 2012-2016
  5.7.4 Sutent Sales Forecast, 2017-2023
  5.7.5 Additional Indication Approval.
  5.7.6 Late-Stage Clinical Trials for Additional Uses and Dosage Forms for Sutent
5.8 Nexavar (Bayer/Onyx)
  5.8.1 Nexavar Sales 2011
  5.8.2 Patent Expiry
  5.8.3 Nexavar Sales Forecast, 2012-2016
  5.8.4 Nexavar Sales Forecast, 2017-2023
5.9 Sprycel (Bristol-Myers Squibb)
  5.9.1 Sprycel Sales 2011
  5.9.2 Patent Expiry
  5.9.3 Sprycel Sales Forecast, 2012-2016
  5.9.4 Sprycel Sales Forecast, 2017-2023
5.10 Arimidex (AstraZeneca)
  5.10.1 Arimidex Sales 2011
  5.10.2 Patent Expiry
  5.10.3 Arimidex Sales Forecast, 2012-2016
  5.10.4 Arimidex Sales Forecast, 2017-2023


6.1 Overview
6.2 Small-Molecule Lung Cancer Pipeline 2012
  6.2.1 Afatinib (Boehringer Ingelheim), a Second-generation Tyrosine Kinase Inhibitor
  6.2.2 Crizotinib/Xalkori (Pfizer) Receives FDA Approval
6.3 Small-Molecule Breast Cancer Pipeline 2012
  6.3.1 Line Extensions
  6.3.2 Halaven (Eisai) Enters Phase III for Non-Small Cell Lung cancer
6.4 Small-Molecule Colorectal Cancer Pipeline 2012
  6.4.1 Regorafenib/BAY73-4506 (Bayer), a Promising Candidate Targeting Multiple Pathways including VEGF
  6.4.2 Perifosine/KRX 0401 (Keryx/Aeterna Zentaris), Oral P13K Inhibitor Granted Fast Track Status by FDA
6.5 Small-Molecule Stomach Cancer Pipeline 2012
  6.5.1 Line Extensions
  6.5.2 Telatinib, ACT Biotech's Lead Anti-angiogenic Pipeline Product
6.6 Small-Molecule Prostate Cancer Pipeline 2012
  6.6.1 MDV 3100 (Astellas/Medivation), an Oral Androgen Receptor Antagonist
  6.6.2 CB7630 (Centocor Ortho Biotech) Formulated as a Prodrug for Prostrate Cancer
6.7. Small-Molecule Multiple Myeloma Pipeline, 2012
  6.7.1 Proteasome Inhibitors: the Next Generation CEP 18770 (Cephalon) - Late-phase Trials for Relapsed/Refractory Multiple Myeloma Marizomib (Nereus) Shows Promising Results in Early-phase Trials MLN 9708 (Takeda), First Oral Proteosome Inhibitor to Reach Clinical Trials CEP 28331 (Cephalon), Another Proteosome Inhibitor in Development
  6.7.2 Immunomodulators: The Past or the Future for Myeloma Treatment? Afinitor (Novartis) Shows Positive Data for Myeloma in Early-stage Trials E-Selectin Antagonists (GlycoMimetics)
  6.7.3 Histone Deacetylase Inhibitors: An Important Field Istodax (Celgene Corporation) in Late-phase Trials for Myeloma and T-cell Lymphoma Zolinza (Merck & Co.) in Late-phase Development for Mesothelioma and Other Indications AR 42 (Arno), a Histone Deacetylase Inhibitor Showing Early Promise Givinostat (Italfarmaco) in Trials for Relapsed/Refractory Multiple Myeloma Patients HDAC6 Inhibitors (Acetylon) Targeting Multiple Myeloma
  6.7.4 Kinase Inhibitors/Signal Transduction Blockers: The Largest Pipeline Sector Votrient (GlaxoSmithKline): Late-phase Development for Ovarian, Breast and Soft Tissue Sarcoma Lenocta (VioQuest), a Promising Tyrosine Phosphatise Inhibitor Ruxolitnib (Novartis) in Late-phase Trials for Multiple Indications Lestaurtnib (Cephalon), a Tyrosine Kinase Inhibitor Reaches Phase III for Myeloma and Prostrate Cancer Masitnib (AB Science) in Late-phase Trials for a Range of Cancer Indications AT 9283 (Astex Therapeutics), a JAK-2 & Mitosis Inhibitor in Multiple Trials Dovitnib (Novartis) Begins Phase II Testing for Myeloma and Other Indications P276 (Piramal Life Sciences) CDK1/4 Inhibitor Targeting Multiple Indications PD332991 (Pfizer) Enters Late-phase Development for Multiple Indications ENMD 2076 (EntreMed) Receives Orphan Drug Status in the US AT 7519 (Astex Therapeutics), an Injectable CDK Inhibitor with Promise in Mono and Combination Therapy MLN 8237 (Takeda), a Promising Oral Bioavailable Drug in Trials for Multiple Indications Estybon (Onconova) in Development for Multiple Cancer Indications CX 4945 (Cylene), a CK2 Inhibitor in Early Development GDC 0941 (Roche), a Promising Candidate in Early-phase Trials for Multiple Indications INK 128 (Intellikine): Targeting TORC1/2 Pathway SF 1126 (Semafore), an Injectable Peptide Prodrug Targeting PI 3-Kinase Pathway SNS 032 (Sunesis/Bristol-Myers Squibb) in Early Development for Multiple Indications Sprycel (Otsuka/Bristol-Myers Squibb): Abl/Src Tyrosine Tinase Inhibitor in Multiple Trials TG 02 (Tragara/S*BIO) in Trials for Relapsed/Refractory Myeloma R763 (Rigel), an Aurora Kinase Inhibitor with Anti-Myeloma Promise
  6.7.5 Heat Shock Protein (HSP) Modulators AUY 922 (Novartis) in Early Trials for Solid Tumour and Myeloma KW 2478 (Kyowa Hakko Kirin), a HSP90 Inhibitor intended for Non-Hodgkin's Lymphoma and Other Indications NVP BEP800 (Novartis): HSP90 Inhibitor with Early Promise
  6.7.6 Apoptosis Inducers: Four Products at Phase II GCS 100 (Prospect Therapeutics) in Late-stage Development for Multiple Indications Amplimexon (AmpliMed) - US Orphan Drug Designation for Several Indications Trisenox (Nippon Shinyaku), a Promising Apoptotic with Unknown Mechanism Noscapine (Cougar Biotechnology), an Orally Active Alkaloid Showing Early Promise BMS 833923 (Bristol-Myers Squibb): Targets Hedgehog Pathway SNS 01-T (Senesco): siRNA Product Designated US Orphan Drug Status
  6.7.7 Other Small-Molecule Myeloma Products Products in Phase II Amnolake (CytRx) in Late-stage Development for Multiple Indications Coprexa TM (Attenuon) in Phase II Trials Brostallacin (Cell Therapeutics), a Potential Chemotherapy Agent CYT 997 (YM BioSciences) in Late-phase Development in Australia ARRY 520 (Array BioPharma), a Promising Injectable for AML and Myeloma Zinapar (Ziopharm) in Development for Multiple Indications Products in Phase I Quadramet (EUSA Pharma) in Late-stage Trials for Metastasis and Prostate Cancer LC1 (Leuchemix): Orally-bioavailable Parthenolide Analogue MLN 4924 (Takeda): Targets Multiple Oncology Indications OPB 31121 (Otsuka), a Transcription Factor Regulator/STAT Inhibitor in Early-Phase Development Zalypsis (PharmaMar), an Injectable Candidate for Lymphoma and Solid Tumours Products in Preclinical Studies INNO 206 (CytRx), Showing Early Promise in Myeloma Ostabolin-C (Zelos), a Parathyroid Hormone Analogue with Potential in Myeloma Treatment IRE1-alfa inhibitor (Mannkind), First-in-class Candidate Targeting Novel Pathways HIF Signalling Inhibitors (Elara) PS 031291 (Ligand), Promising Chemokine Receptor 1 (CCR1) Antagonist SST 0001 (Sigma-Tau), Aimed at bFGF Growth Factors CGEN 928 (Compugen), Targeting Multiple Myeloma Ubiquitin-Specific Peptidase 7 (USP7) Inhibitors by Progenra
6.8 Small-Molecule Epigenetic Therapy Pipeline, 2012
  6.8.1 HDAC Inhibitors PXD-101 (Belinostat, TopoTarget/Spectrum Pharmaceuticals) LBH589 (Panobinostat, Novartis), Gains Orphan Drug Status for Hodgkin's Lymphoma Entinostat (Syndax Pharmaceuticals), Targeting Breast and Lung Indications 4SC-201 (Resminostat, 4SC), Oral Pan-HDAC Inhibitor in Development for Variety of Cancers MGCD-0103 (Mocetinostat, MethylGene), Targeting Class I/IV Histone Deacetylases SB939 (S*BIO), First Anti-cancer Therapy Developed in Singapore ACY-1215, Acetylon Pharmaceuticals' Second Generation HDAC Inhibitor for Multiple Myeloma Valproic Acid, an Epilepsy Drug in Multiple Trials for Cancer Indications
  6.8.2 DNMT Inhibitors SGI-110, Astex Pharmaceuticals' Second Generation DNMT Inhibitor CP-4200 (Clavis Pharma) - Showing Early-stage Promise


7.1 SWOT Chart for Small-Molecule Cancer Therapies Market 2013-2023
7.2 Strengths
  7.2.1 Cancer Treatment has Proven Commercial Potential
  7.2.2 High Profile Nature of Cancer
  7.2.3 Off-Label Prescriptions are Common
  7.2.4 Strong Drug Development Incentives
7.3 Weaknesses
  7.3.1 Tumours and Multidrug Resistance (MDR)
  7.3.2 Pricing-Out the Developing World?
7.4 Opportunities
  7.4.1 Cancer is a Key Business Area for the Pharmaceutical Industry
  7.4.2 Rising Incidence of Cancer Aging Populations Smoking Obesity The Developing World
  7.4.3 Greater Understanding of Cancer Gives Opportunities in the Cancer Treatment Industry
  7.4.4 Advanced Diagnostics with Pharmacogenomics: Impact on Cancer Therapies
  7.4.5 Live Licensing and In-Life Testing
  7.4.6 Convenience of Targeted Drugs versus Chemotherapy
7.5 Threats
  7.5.1 Healthcare Spending Restraints Threaten Cancer Drug Revenues
  7.5.2 The Cost-Effectiveness Debate
  7.5.3 Governments are a Leading Payer for Drugs
  7.5.4 Efficacy, Toxicity and Alternative Treatments
7.6 Biosimilars and Generics: Opportunity or Threat?
7.7 Personalised Medicine and Cancer
  7.7.1 Biomarkers and Diagnostics
  7.7.2 Small-Molecule (Metabolic) Biomarkers
  7.7.3 Cancer Heterogeneity
  7.7.4 Pharmacogenomics
  7.7.5 Genome Screening
  7.7.6 Theranostics


8.1 Dr Martin Bonde, CEO, EpiTherapeutics
  8.1.1 Potential for Histone Methyltransferase Inhibitors
  8.1.2 Future of Epigenetics Research
  8.1.3 Histone Methyltransferase Inhibitors on Market within Decade?
  8.1.4 Challenges in Developing Epigenetic Therapies
  8.1.5 Benefits of University Spin-Outs
8.2 Dr Joanna Horobin, President and CEO, Syndax Pharmaceuticals
  8.2.1 On Challenges Facing Cancer Therapies
  8.2.2 On Selective Targeting of Therapies
  8.2.3 On Drug Resistance and Targeted Therapies
  8.2.4 On Drug Resistance and Market Opportunity
  8.2.5 On Entinostat, Lung and Breast Cancer Therapies
8.3 Interview with an External Authority (Views Given Anonymously)
  8.3.1 Obesity is a Strong Risk Factor for Cancer
  8.3.2 Multiple Myeloma Treatment: Proactive versus Reactive
  8.3.3 Treatment Options for Obese Patients
  8.3.4 Multiple Myeloma Incidence Will Increase Due To Obesity
8.4 Interview with Dr Kent C. Osborne, Baylor College of Medicine
  8.4.1 On Challenges in Developing Anti-Cancer Therapies
  8.4.2 On Major Areas of Focus
  8.4.3 On Cancer Vaccines
  8.4.4 On Areas with Potential for Increased Revenue Generation
  8.4.5 On R&D Pipeline
  8.4.6 On Difficulties Conducting Clinical Trials


9.1 Small-Molecule Cancer Therapies Market Offers Promise
9.2 Leading Products in Small-Molecule Cancer Therapies Market
9.3 The US Will Remain the World's Largest Small-Molecule Cancer Therapies Market
9.4 India and China Will be the Fastest-Growing National Markets
9.5 R&D Pipelines for Many Cancer Types Are Strong
9.6 Concluding Remarks


Table 2.1 Leading Causes of Death Worldwide, 2008 & 2015
Table 2.2 Most-Common Cancers by Incidence, 2008
Table 2.3 Most-Common Cancers by Mortality, 2008 & 2015
Table 2.4 Five-Year Survival Rates of Nine Cancers in the UK, 2009
Table 2.5 Categories of Anti-Cancer Drug, 2012
Table 2.6 Common Side-effects of Traditional Antineoplastic Chemotherapy
Table 2.7 Subcategories of TANs, 2012
Table 3.1 Small-Molecule Cancer Therapies Market: World Sales Forecast, 2011-2016
Table 3.2 Small-Molecule Cancer Therapies Market: World Sales Forecast, 2017-2023
Table 3.3 Small-Molecule Cancer Market: Top Ten Products - Sales and Market Shares, 2011, 2016 & 2023
Table 4.1 Leading Small-Molecule Cancer Therapies: National Market Forecasts, 2011-2023
Table 5.1 Glivec/Gleevec Sales for US and RoW, 2009-2011
Table 5.2 Glivec/Gleevec Sales Forecast, 2011-2016
Table 5.3 Glivec/Gleevec Sales Forecast, 2017-2023
Table 5.4 Glivec/Gleevec: Sales Drivers and Restraints, 2012-2023
Table 5.5 Revlimid Sales Forecast, 2011-2016
Table 5.6 Revlimid Sales Forecast, 2017-2023
Table 5.7 Revlimid: Sales Drivers and Restraints, 2012-2023
Table 5.8 Alimta Sales for US and RoW, 2009-2011
Table 5.9 Alimta Sales Forecast, 2011-2016
Table 5.10 Alimta Sales Forecast, 2017-2023
Table 5.11 Alimta: Sales Drivers and Restraints, 2012-2023
Table 5.12 Velcade Sales by Company, 2009-2011
Table 5.13 Velcade Sales Forecast, 2011-2016
Table 5.14 Velcade Sales Forecast, 2017-2023
Table 5.15 Velcade: Sales Drivers and Restraints, 2012-2023
Table 5.16 Tarceva Sales Forecast, 2011-2016
Table 5.17 Tarceva Sales Forecast, 2017-2023
Table 5.18 Tarceva: Sales Drivers and Restraints, 2012-2023
Table 5.19 Taxotere: Approved Indications, 2012
Table 5.20 Taxotere Sales by Region, 2009-2011
Table 5.21 Taxotere Sales Forecast, 2011-2016
Table 5.22 Taxotere Sales Forecast, 2017-2023
Table 5.23 Taxotere: Sales Drivers and Restraints, 2012-2023
Table 5.24 Sutent Sales Forecast, 2011-2016
Table 5.25 Sutent Sales Forecast, 2017-2023
Table 5.26 Sutent: Sales Drivers and Restraints, 2012-2023
Table 5.27 Nexavar Sales Forecast, 2011-2016
Table 5.28 Nexavar Sales Forecast, 2017-2023
Table 5.29 Nexavar: Sales Drivers and Restraints, 2012-2023
Table 5.30 Sprycel Sales for US and RoW, 2009-2011
Table 5.31 Sprycel Sales Forecast, 2011-2016
Table 5.32 Sprycel Sales Forecast, 2017-2023
Table 5.33 Sprycel: Sales Drivers and Restraints, 2012-2023
Table 5.34 Arimidex Sales for US and RoW, 2009-2011
Table 5.35 Arimidex Sales Forecast, 2011-2016
Table 5.36 Arimidex Sales Forecast, 2017-2023
Table 5.37 Arimidex: Sales Drivers and Restraints, 2012-2023
Table 6.1 Abbreviations Used in Chapter 6
Table 6.2 Selected Small-Molecule Lung Cancer Pipeline Candidates in Phase III, 2012
Table 6.3 Selected Small-Molecule Lung Cancer Pipeline Candidates in Phase II/III, 2012
Table 6.4 Selected Small-Molecule Breast Cancer Pipeline Candidates in Phase II & III, 2012
Table 6.5 Selected Small-Molecule Colorectal Cancer Pipeline Candidates in Phase II & III, 2012
Table 6.6 Selected Small-Molecule Stomach Cancer Pipeline Candidates in Phase II & III, 2012
Table 6.7 Selected Small-Molecule Prostate Cancer Pipeline Candidates in Phase II & III, 2012
Table 6.8 Small-Molecule Pipeline Products for Multiple Myeloma, 2012
Table 6.9 Small-Molecule Multiple Myeloma Pipeline: Proteasome Inhibitors, 2012
Table 6.10 Small-Molecule Multiple Myeloma Pipeline: Immunomodulators, 2012
Table 6.11 Small-Molecule Multiple Myeloma Pipeline: Histone Deacetylase Inhibitors, 2012
Table 6.12 Small-Molecule Multiple Myeloma Pipeline: Kinase Inhibitor/Signal Transduction Blockers, 2012
Table 6.13 Small-Molecule Multiple Myeloma Pipeline: Heat Shock Protein Modulators, 2012
Table 6.14 Small-Molecule Multiple Myeloma Pipeline: Apoptosis Inducers, 2012
Table 6.15 Other Small-Molecule Myeloma Products: Phase II Pipeline, 2012
Table 6.16 Other Small-Molecule Myeloma Products: Phase I Pipeline, 2012
Table 6.17 Other Small-Molecule Myeloma Products: Preclinical Pipeline, 2012
Table 6.18 Selected Small-Molecule HDAC Inhibitor Pipeline Candidates, 2012
Table 6.19 Ongoing Clinical Trials for PXD-101 (Belinostat), 2012
Table 7.1 STEP Analysis of World Small-Molecule Cancer Drugs Market, 2013-2023
Table 7.2 SWOT Analysis of World Small-Molecule Cancer Drugs Market: Strengths and Weaknesses, 2013-2023
Table 7.3 SWOT Analysis of World Small-Molecule Cancer Drugs Market: Opportunities and Threats, 2013-2023
Table 9.1 Small-Molecule Cancer Drug Market: Top Ten Products - Sales and Market Shares, 2011
Table 9.2 Small-Molecule Cancer Drugs Market by Country, 2011, 2016, 2020 & 2023


Figure 2.1 Leading Causes of Death Worldwide, 2008 & 2015
Figure 2.2 Most-Common Cancers by Incidence, 2008
Figure 2.3 Most-Common Cancers by Mortality, 2008
Figure 2.4 Most-Common Cancers by Mortality, 2015
Figure 2.5 Five-Year Survival Rates of Nine Cancers in the UK, 2009
Figure 3.1 Small-Molecule Cancer Therapies Market: World Sales Forecast, 2011-2016
Figure 3.2 Small-Molecule Cancer Therapies Market: World Sales Forecast, 2017-2023
Figure 3.3 Small-Molecule Cancer Therapies: Sales Shares for Leading Products, 2011
Figure 3.4 Small-Molecule Cancer Therapies: Sales Shares for Leading Products, 2016
Figure 3.5 Small-Molecule Cancer Therapies: Sales Shares for Leading Products, 2020
Figure 3.6 Small-Molecule Cancer Therapies: Sales Shares for Leading Products, 2023
Figure 4.1 Leading National Small-Molecule Cancer Therapies Market Forecasts, 2011-2023
Figure 4.2 National Small-Molecule Cancer Therapies Market Forecasts: Lower Range, 2011-2023
Figure 4.3 Small-Molecule Cancer Therapies: Leading National Markets, 2011
Figure 4.4 Small-Molecule Cancer Therapies: Leading National Markets, 2016
Figure 4.5 Small-Molecule Cancer Therapies: Leading National Markets, 2020
Figure 4.6 Small-Molecule Cancer Therapies: Leading National Markets, 2023
Figure 5.1 Glivec/Gleevec Sales for US and RoW, 2011
Figure 5.2 Glivec/Gleevec Sales Forecast, 2011-2023
Figure 5.3 Revlimid Sales Forecast, 2011-2023
Figure 5.4 Alimta Sales for US and RoW, 2011
Figure 5.5 Alimta Sales Forecast, 2011-2023
Figure 5.6 Velcade Sales by Company, 2011
Figure 5.7 Velcade Sales Forecast, 2011-2023
Figure 5.8 Tarceva Sales Forecast, 2011-2023
Figure 5.9 Taxotere Sales by Region, 2011
Figure 5.10 Taxotere Sales Forecast, 2011-2023
Figure 5.11 Sutent Sales Forecast, 2011-2023
Figure 5.12 Nexavar Sales Forecast, 2011-2023
Figure 5.13 Sprycel Sales for US and RoW, 2011
Figure 5.14 Sprycel Sales Forecast, 2011-2023
Figure 5.15 Arimidex Sales by Region, 2011
Figure 5.16 Arimidex Sales Forecast, 2011-2023
Figure 9.1 Small-Molecule Cancer Therapies Market: World Sales Forecast, 2011, 2013, 2016, 2020 & 2023


AB Science
Abbott Laboratories
Abraxis BioScience
Acetylon Pharmaceuticals
ACT Biotech
Active Biotech
Adeona (formerly Pipex)
AERES Biomedical
Aeterna Zentaris
Allos Therapeutics
Ambit Biosciences
American Society of Clinical Oncology (ASCO)
American Society of Hematology (ASH)
APP Pharmaceuticals (part of the Fresenius Kabi Group)
ARIAD Pharmaceuticals
Arizona University
Array BioPharma
Ascenta Therapeutics
Astellas Pharma
Astex Pharmaceuticals
Astex Therapeutics
AVEO Pharmaceuticals
Barr Laboratories
Bayer Healthcare
Baylor College of Medicine
Biogen Idec
Biotech Research & Innovation Centre [Copenhagen, Denmark]
BiPar Sciences (a subsidiary of Sanofi)
Boehringer Ingelheim
Bristol-Myers Squibb (BMS)
British Biotech
Canadian National Research Council
Cancer Research Technology
Cancer Research UK
Cancer Science Institute of Singapore (CSI Singapore)
Cell Therapeutics
Centres for Disease Control and Prevention (US)
Centocor Ortho Biotech
Centocor Research & Development
Cetus Corporation
China's State Food and Drug Administration
Clavis Pharma
Cleveland Clinic
Columbia University
Concordia Pharmaceuticals
Constellation Pharmaceuticals
Cougar Biotechnology
CTI Technologies
Cyclacel Pharmaceuticals
Daiichi Sankyo
Dana Farber Cancer Institute
Dr. Reddy's Laboratories
Elara Pharmaceuticals
Eleison Pharmaceuticals
Eli Lilly
European Medicines Agency (EMEA/EMA)
European Molecular Biology Laboratory (EMBL)
EUSA Pharma (formerly Cytogen)
Facet Biotech
Food and Drug Administration (US FDA)
Fresenius Kabi
Genentech (now part of Roche)
Generex Biotechnology
GlaxoSmithKline (GSK)
Gloucester Pharmaceuticals
GPC Biotech
Greenwich Therapeutics
GTC Biotherapeutics
Harvard University
Human Genome Sciences
ILEX Oncology
ImClone Systems (a subsidiary of Eli Lilly)
Immune System Therapeutics
Infinity Pharmaceuticals
Innate Pharma
Intas Biopharmaceuticals
International Cancer Genome Consortium
International Myeloma Working Group
Introgen Therapeutics
Isis Pharmaceuticals
Johnson & Johnson (J&J)
Kadmon Pharmaceuticals
Karyopharm Therapeutics
Keryx Biopharmaceuticals
Keyaku Zentaris
Kosan Biosciences
KTB Tumorforschungs
Kyowa Hakko Kirin
Les Laboratoires Servier
Leukaemia and Lymphoma Society
Marlborough Research and Development
Marshall Edwards
MD Anderson Cancer Center
Merck & Co.
Merck KGaA
Merck Serono (part of Merck KGaA)
Millennium Pharmaceuticals (now part of Takeda)
Mount Sinai Medical Center [US]
Multiple Myeloma Research Consortium
Multiple Myeloma Research Foundation
Mylan Pharmaceuticals
Natco Pharma
National Cancer Institute (NCI) [US]
National Cancer Institute (US)
National Health Service (NHS) [UK]
National Institute for Clinical Excellence (NICE) [UK]
National University Cancer Institute Singapore (NCIS)
NCIC Clinical Trials Group
Nektar Therapeutics
Nerviano Medical Sciences
Nippon Shinyaku
Novo Nordisk
Ohio State University
OncoGenex Pharmaceuticals
Ono Pharmaceuticals
Onyx Pharmaceuticals
Ortho Biotech
OSI Pharmaceuticals
Oxford University
Par Pharmaceutical
PDL BioPharma
PharmaCenter Basel
Pharmaceutical Research and Manufacturers of America (PhRMA) [US]
Pierre Fabre Pharmaceuticals
Piramal Life Sciences
PolaRx Biopharmaceuticals
Poniard Pharmaceuticals
Prospect Therapeutics
Protein Design
Radient Pharmaceuticals
Rockefeller University
Roxane Laboratories
Salk Institute for Biological Studies
Sandoz (part of Novartis)
Sanofi (sanofi-aventis)
Scripps Institution of Oceanography
Seattle Genetics
Signal Pharmaceuticals
Sloan-Kettering Institute
Spectrum Pharmaceuticals
Stada Arzneimittel
Sun Pharmaceuticals
Syndax Pharmaceuticals
Synta Pharmaceuticals
Taiho Pharma
Tapestry Pharmaceuticals
Teva Pharmaceutical Industries
Texas A&M University
The NCIC Clinical Trials Group (Canada)
Threshold Pharmaceuticals
Tufts University
University of Basel PharmaCenter (PharmaCenter Basel)
University of Cambridge
University of Kentucky College of Pharmacy
University of Michigan
University of San Diego
US National Cancer Institute
US National Comprehensive Cancer Network
Wayne State University
World Health Organization (WHO)
XTL Biopharmaceuticals
Yakult Honsha
Yeda Research and Development Company
YM Biosciences
Zenyaku Kogyo
Skip to top

Ask Your Question

Small-Molecule Targeted Cancer Therapies: World Market 2013-2023
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: